aTYR PHARMA INC Segment Reporting Other Item Amount
aTYR PHARMA INC (ATYR) reported Segment Reporting Other Item Amount of -$571.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Segment Reporting
us-gaap:SegmentReportingOtherItemAmount · last filed 2026-08-07
- aTYR PHARMA INC segment reporting other item amount for the quarter ending 2026-06-30 was -$571.00K.
- aTYR PHARMA INC segment reporting other item amount for the quarter ending 2026-03-31 was -$644.00K.
- aTYR PHARMA INC segment reporting other item amount for the quarter ending 2025-12-31 was -$832.00K.
- aTYR PHARMA INC segment reporting other item amount for the quarter ending 2025-09-30 was -$999.00K.
- aTYR PHARMA INC segment reporting other item amount for fiscal 2025 was -$3.50M.
- aTYR PHARMA INC segment reporting other item amount for fiscal 2024 was -$3.89M.
- aTYR PHARMA INC segment reporting other item amount for fiscal 2023 was -$4.52M, a 526.20% decline from fiscal 2022.
- aTYR PHARMA INC segment reporting other item amount for fiscal 2022 was $1.06M.
| Period end | Segment Reporting Other Item Amount 3 month | Segment Reporting Other Item Amount 6 month | Segment Reporting Other Item Amount 9 month | Segment Reporting Other Item Amount 12 month | Segment Reporting Other Item Amount 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$571.00K 10-Q · filed 2026-08-07 | -$1.22M 10-Q · filed 2026-08-07 | -$2.05M derived: sum of 3 quarters · filed 2026-08-07 | -$3.05M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2026-03-31 | -$644.00K 10-Q · filed 2026-05-15 | -$1.48M derived: sum of 2 quarters · filed 2026-05-15 | -$2.48M derived: sum of 3 quarters · filed 2026-05-15 | -$3.26M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-12-31 | -$832.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$1.83M derived: sum of 2 quarters · filed 2026-03-05 | -$2.61M derived: sum of 3 quarters · filed 2026-08-07 | -$3.50M 10-K · filed 2026-03-05 | |
| 2025-09-30 | -$999.00K 10-Q · filed 2025-11-06 | -$1.78M derived: sum of 2 quarters · filed 2026-08-07 | -$2.67M 10-Q · filed 2025-11-06 | -$3.52M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-06-30 | -$781.00K 10-Q · filed 2026-08-07 | -$1.67M 10-Q · filed 2026-08-07 | -$2.52M derived: sum of 3 quarters · filed 2026-08-07 | -$3.41M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-03-31 | -$892.00K 10-Q · filed 2026-05-15 | -$1.74M derived: sum of 2 quarters · filed 2026-05-15 | -$2.63M derived: sum of 3 quarters · filed 2026-05-15 | -$3.63M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | -$852.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$1.73M derived: sum of 2 quarters · filed 2026-03-05 | -$2.74M derived: sum of 3 quarters · filed 2026-03-05 | -$3.89M 10-K · filed 2026-03-05 | $3.89M 10-K · filed 2025-03-13 |
| 2024-09-30 | -$882.00K 10-Q · filed 2025-11-06 | -$1.89M derived: sum of 2 quarters · filed 2025-11-06 | -$3.04M 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | -$1.01M 10-Q · filed 2025-08-07 | -$2.16M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | -$1.15M 10-Q · filed 2025-05-07 | ||||
| 2023-12-31 | -$4.52M 10-K · filed 2026-03-05 | $4.52M 10-K · filed 2025-03-13 | |||
| 2022-12-31 | $1.06M 10-K · filed 2025-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |